Prosthetic foot technologies — evidence summary: summarize clinical evidence, limitations, and policy translations for microprocessor-controlled feet, energy-return (ESAR) and novel linkage feet, and other advanced foot systems.
1. Microprocessor-controlled feet (e.g., Proprio Foot, PowerFoot BiOM, iWalk BiOM, iWalk, Proprio)
2. Evidence for microprocessor-controlled feet is limited and largely based on small studies that measure short-term kinematic or surrogate outcomes rather than robust patient-centered functional outcomes (e.g., daily step counts, fall rates, energy expenditure, long-term QoL). Key studies show improved ankle motion and some normalization of ankle power (BiOM) and improved inter-limb symmetry on stair ascent (Proprio), but findings are preliminary and inconsistent across tasks such as stair descent.
3. A small randomized crossover trial and several nonrandomized studies (e.g., Highsmith et al., 2016 comparing Genium vs C-Leg for transfemoral amputees) suggest certain microprocessor-controlled knee/foot systems can improve stair performance, multi-directional stepping, some ADL domains, and user preference in selected community ambulators, but generalizability is limited.
4. Energy-storing-and-return (ESAR) and novel linkage feet (e.g., Pro-Flex, Vari-Flex, new linkage systems) demonstrate increased prosthetic ankle power and range of motion, with some data indicating reduced contralateral limb loading and potential to transfer more propulsive energy to whole-body center-of-mass propulsion. Sample sizes are small and clinical implications (e.g., osteoarthritis risk reduction) remain uncertain.
5. Bionic / powered feet (e.g., BiOM, iWalk PowerFoot) have shown restoration of ankle power and increased ankle motion in laboratory and small clinical samples, but do not consistently reduce compensatory hip strategies and evidence of meaningful improvements in community ambulation, fall reduction, energy expenditure, or long-term outcomes is inadequate.
6. Overall evidence limitations: studies are often small, nonrandomized, short-term, industry-funded, and emphasize intermediate/biomechanical outcomes. Systematic reviews (including Washington State HTA) concluded there is insufficient evidence to draw definitive conclusions about comparative effectiveness, safety, or cost-effectiveness for microprocessor-controlled foot devices.
7. Policy translation: Given the limited and inconsistent evidence, coverage is generally reserved for members with documented K-level functional status consistent with device intent (typically K3 or above for microprocessor-controlled foot devices) when clinical documentation supports functional benefit and device fitting/training by qualified providers. Devices lacking robust evidence or used for unsupported indications (e.g., gait management in spinal cord injury) are considered not covered or investigational per policy.